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Complex traitsA wealth of novel lipid loci have been identiﬁed through a variety of approaches focused on common and low-
frequency variation and collaborativemetaanalyses inmultiethnic populations. Despite progress in identiﬁcation
of loci, the task of determining causal variants remains challenging. This work will undoubtedly be enhanced by
improved understanding of regulatory DNA at a genomewide level as well as newmethodologies for interrogat-
ing the relationships between noncoding SNPs and regulatory regions. Equally challenging is the identiﬁcation of
causal genes at novel loci. Some progress has been made for a handful of genes and comprehensive testing of
candidate genes using multiple model systems is underway. Additional insights will be gleaned from focusing
on low frequency and rare coding variation at candidate loci in large populations. This article is part of a Special
Issue entitled: From Genome to Function.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Complex traits, including continuously distributed traits such as
blood pressure, height, body-mass-index, plasma lipids, and others, are
subject to immense genetic variation and environmental inﬂuence [1,
2]. This property has made pinpointing the exact genetic contributors
for a given trait challenging. Given that many of these traits, as well as
diseaseswith polygenic inheritance, have signiﬁcant clinical implications
or burden, there remains amajor interest in comprehensively identifying
all the genes that contribute to these phenotypes, themagnitude of their
contribution, and themechanisms of their effects. Recent human genetic
advances focused on genotyping commonvariants have provided a route
to better interrogate theheritability of such traits. Such genome-wide as-
sociation studies (GWAS) determine genotypes at thousands to millions
of common single nucleotide polymorphisms (SNPs) across the genome
in individualsmeasured for a trait or disease of interest and test the asso-
ciation of the allele at each SNPwith a quantitative trait or disease status
[3–5]. These studies have been applied to numerous complex traits and
have uncovered hundreds of novel loci signiﬁcantly associated with dis-
eases and their risk factors.
While useful as starting points for uncovering new loci inﬂuencing a
trait, GWASs themselves often require further validation of causal genes
and variants. This is because GWASs interrogatemany common variants
with usually small effect sizes [6,7]. Thus the actual contribution of all
genetic variation at a given locus to a trait cannot be ascertained fromnome to Function.
r).
19104, USA. Tel.: +1 215 573the effect of the associated common variant alone. Moreover, since
most common variants that are genotyped on SNP genotyping arrays
are noncoding in nature, it is often difﬁcult to assign an associated
variant at a locus to a single gene without further experimental
follow-up [6,7]. However, when GWAS is coupled with candidate gene
sequencing at the extremes of a phenotypic distribution, it can be a
powerful tool for establishing a novel gene inﬂuencing a trait as well
as providing a directionality of the relationship between a gene's ex-
pression or function and the trait. A recent example is the identiﬁcation
of variants at or near the GCKR gene with plasma triglyceride (TG)
levels. Initially reported in the ﬁrst GWAS for plasma lipids, common
non-coding variants at this locuswere robustly and consistently associat-
ed with plasma TG, as well as with fasting glucose levels, in subsequent
follow-up studies and metaanalyses [8,9]. Subsequently, several groups
sought to identify functional coding variants in GCKR that inﬂuenced its
role in TG and glucose metabolism [10,11]. One study, which involved
sequencing GCKR in individuals from the ClinSeq medical resequencing
project, identiﬁed 19 missense variants, many of which were rare in
frequency and deleterious to protein function in vitro, and demonstrated
association of these variants to TG in that cohort [12]. Similar approaches
are underway to establish causality and identify functional variants in
novel loci for plasma lipids and other complex traits identiﬁed through
GWAS.
2. Genome-wide association studies for plasma lipids
Plasma high-density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C) and triglycerides (TG) have been among
the most commonly interrogated complex traits since the advent of
genome-wide association studies (GWAS) in the mid-2000s. Because of
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they have been commonly studied in multiethnic populations. The ﬁrst
large GWASs for lipids were published in 2008 and involved almost
9000 individuals [8,9,13]. These studies identiﬁed both known loci previ-
ously shown to regulate lipidmetabolismaswell as 8novel loci associated
with at least one lipid trait. These included the SORT1/CELSR2/PSRC1 gene
locus and the NCAN/CILP2/PBX4 gene locus for LDL-C, the GALNT2 gene
locus and MVK/MMAB gene locus for HDL-C, and the TBL2, MLXIPL,
TRIB1, and ANGPTL3 gene loci for TG. Several of the lead SNPs for these
loci were also associated with additional lipid traits. For example, SNPs
near the GALNT2 gene associatedwith decreased HDL-C were also asso-
ciated with increased plasma TG. Shortly after these loci were initially
reported, a metaanalysis in almost 20,000 individuals, including associ-
ation testing in the participants of the Framingham Heart Study and
additional European cohorts, replicated the previously reported associ-
ations for these loci and identiﬁed 11 new loci associated with at least
one lipid trait [14]. Since these initial reports, follow-up studies and
metaanalyses subsequently validated these loci and identiﬁed additional
ones [15–17].
Of note are two large metaanalyses from the Global Lipids Genetics
Consortium (GLGC), a collaborative organization led by the groups
who reported the initial 2008 study. In 2010, the GLGC reported a
GWAS for total cholesterol (TC), HDL-C, LDL-C, and TG in more than
100,000 European individuals [16]. This study yielded 95 genetic loci
associated with at least one plasma lipid trait, 59 of which were novel
associations. The results included replications in a smaller sample of
East Asian, South Asian and African American cohorts, as well as sex-
speciﬁc analyses and testing of the lipid-associated SNPs with incidence
of coronary artery disease (CAD).
A second study from the consortium, published in late 2013, ex-
panded this effort to include more than 188,000 individuals and identi-
ﬁed an additional 62 novel loci, 30 of which had never been previously
connected to lipid metabolism [15]. As part of this effort, the investiga-
tors selected 65 loci to interrogate on a cardiovascular trait- and meta-
bolic trait-centric array (Metabochip) in a ﬁne-mapping effort for the
common variants [15]. Additionally, to assess the potential pleiotropic
effects of the lipid-associated SNPs on other cardiometabolic traits,
they tested the association of these SNPs with fasting glucose, systolic
and diastolic blood pressure, BMI, waist-to-hip ratio, and incidence of
type 2 diabetes and CAD in subsets of the 188,000 subjects. They
found that several lipid-associated SNPs were also associated with one
ormore of these traits aswell. In total, the authors note 240 geneswithin
1 kilobase (kb) of the lead SNPs for the 62 novel loci, highlighting the
challenging task of identifying the causal gene(s) at these loci.
3. Upstream issues—from locus to causal variant
Despite the wealth of novel loci for complex traits, few of the causal
functional variants that biologically underlie the genetic associations
have been conclusively identiﬁed. This is in part due to the limitation
of SNPs that can be interrogated on GWAS genotyping arrays and the
need for indirect imputation of SNPs in linkage disequilibrium with
the genotyped SNPs [7,18,19]. While this approach often allows identi-
ﬁcation of a causal ‘region’ containing SNPs associatedwith the trait, it is
usually insufﬁcient to identify which SNP at a given region drives the
association and may underestimate the extent of variation at a locus
contributing to a trait. For common noncoding variants that are within
(or in LD with SNPs within) deﬁned promoter or known regulatory re-
gions of nearby genes, one may assess the effects of variants in these
known regulatory regions on gene expression through gene reporter as-
says, binding afﬁnity for speciﬁc transcription factors, and related func-
tional approaches. Such efforts have been done for a limited number of
lipid-associated SNPs, such as those at the LDL cholesterol-associated
chromosome 1p13 locus (containing SORT1) (discussed below) [20].
Another approach to reﬁning the subset of potentially functional
SNPs at a locus is to test the association of a denser region of SNPsfrom a trait-associated LD block in ethnically diverse populations from
that of the initial association [21,22]. Because the sizes and compositions
of SNPhaplotype blocksmay be ethnicity-speciﬁc, genotyping SNPs cor-
responding to a haplotype across diverse ethnicities may ﬁlter out non-
functional SNPs part of the haplotype of the originally tested population.
Most of the initial GWASs for lipids have been done using populations of
European ancestry. Thus, testing the association of lipid-associated SNPs
in non-European populations may allow the ﬁltering of some SNPs at
novel lipid loci. Using this approach, Deo et al. studied approx. 4400 sub-
jects of the JacksonHeart Study and identiﬁed African American-speciﬁc
SNPs at the LPL locus that masked the protective effect of a gain-of-
function coding variant, S447X, in LD with the noncoding variant [23].
This approach is limited by the need to amass sufﬁcient numbers of sub-
jects in non-European cohorts to compare to original European cohorts so
that power does not confound interpretation of multiethnic association
comparisons. This concern is even more important when considering
populations that have undergone extensivemigration and diversiﬁcation
such as those of African ancestry.
New potential to comprehensively ascertain causal variants at the
many novel loci has been gained from efforts such as the Encyclopedia
of DNA Elements (ENCODE) project [24–26]. This collaborative project
used chromatin immunoprecipitation-sequencing (ChIP-Seq) for
many transcription factors across cell lines spanning several tissue
types to annotate DNA regulatory elements functionally important to
transcription at a genome-wide level. Overlaying trait-associated SNPs
with important transcriptional regulatory regions informed from the
ENCODE project offers one systematic means to localize the subset of
potentially causal variants at each locus. An analogous method of prior-
itizing SNPs is to overlay themwith regionswith chromatinmarks or re-
gions of DNase I hypersensitivity, suggesting open chromatin and active
transcription. Maurano et al. utilized the latter approach to catalogue
the distribution of more than 5600 noncoding GWAS-signiﬁcant SNPs
for various traits in terms of their presence in regions of active tran-
scription (DNase I hypersensitivity) [27]. This work demonstrated a
preponderance of trait- or disease-associated SNPs in regions of open
chromatin that were developmentally- or tissue type-speciﬁc in their
regulatory nature. An analogous study demonstrated the cell-type spec-
iﬁcity of chromatin marks and showed that GWAS-associated SNPs
were consistently proximal to such marks [28,29]. They also showed
that marks such as histone 3 lysine 4 trimethylation (H3K4me3) were
highly cell-type speciﬁc and overlapped with 37 GWAS-associated
SNPs for LDL-C in liver. Such integrative studies utilizing the breadth
of genome-wide regulatory DNA annotation data currently available
provide possible paradigms for further honing in on functional SNPs.
Variants can also be interrogated for their effects on chromatin state
throughapproaches such as formaldehyde-assisted isolation of regulatory
element (FAIRE)-sequencing [30]. Here, formaldehyde crosslinking is
used on cell samples heterozygous for a SNP of interest before DNA iso-
lation and the amount of DNA yielded per genotype for a given SNP can
be quantiﬁed comparatively. If, for example, a SNP allele causes the un-
derlying chromatin to become closed, the DNA will remain tightly
bound to the nucleosome and less will be yielded for sequencing.
Such work identiﬁed a functional SNP at the locus containing NR1H3
(encoding LXRα) associated with HDL-C.
4. Downstream issues—from variants to causal genes and biological
mechanisms
An equally if not more important problem in the post-GWAS era for
traits such as plasma lipids is the correct identiﬁcation of the causal
gene at the locus harboring trait-associated SNPs and the elucidation of
the biological mechanisms involved. A few properties of the trait-
associated loci assist in identifying causal genes: lack of multiple genes
at a given locus, proximity within or very near a gene (as opposed to
within regulatory elements many thousands of kb up or downstream
of genes), presence of an expression quantitative trait locus (eQTL) for
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and biological plausibility of a particular gene at the locus regulating the
associated trait. However, these properties are rarely met and are not in
any case deﬁnitive proof of the causal gene, and thus the identiﬁcation of
the causal gene inﬂuencing a trait can be especially difﬁcult to ascertain
for novel loci.
A major focus in identifying causal genes at novel lipid loci has been
to better characterize SNPs at these loci for potential eQTLs in tissues of
relevance to the trait. For lipid traits, these studies have largely focused
on the liver as the tissue underlying allele-speciﬁc expression of causal
genes, because of the predominant role that hepatocytes play in regulat-
ing lipoprotein metabolism. Additional tissues of potential interest to
interrogate for lipid traits include enterocytes, adipocytes, skeletal
myocytes, as well as endothelial cells and macrophages, whichmediate
the interplay of lipoproteins and their role in atherosclerosis. The results
of the lipid GWASs suggested that of the 157 loci associated with lipids,
47 have signiﬁcant eQTLs for at least one gene proximal to the associated
SNPs in liver, subcutaneous, or omental fat [15]. Methods focused on
measuring allele-speciﬁc expression of candidate genes from tissues of
subjects heterozygous for trait-associated SNPs have allowed better at-
tempts to deﬁne new eQTLs from existing SNPs. This approach was
used to deﬁne the causal gene at a novel HDL-C locus containing the
MVK and MMAB genes [31]. Using human hepatocytes heterozygous
for SNPs at this locus, the authors measured the relative abundance of
allele-speciﬁc transcripts for these genes and found that the SNP allele
at this locus associated with lower HDL-C was associated with greater
MMABbut notMVK transcript levels, implicatingMMAB as the gene reg-
ulated by the effects of the LD block containing the tested SNP and thus
as the probable causal gene.
Common variant association studies for lipids have also uncovered
trans-eQTLs, SNPs inﬂuencing the expression of genes indirectly
through affecting expression of their transcriptional regulators. The
study of KLF14, a HDL-C and type 2 diabetes candidate gene, offers a
striking example. SNPs at the locus containing KLF14 were associated
with these traits in GWAS and were also shown in initial studies to be
maternally restricted cis-eQTLs for KLF14 expression in adipose tissue
[32]. Subsequent work in 2011 showed that these same SNPs were
strongly correlated with expression of several genes in adipose tissue
in trans. This study also demonstrated that many of those genes whose
expression was strongly associated with the KLF14 noncoding SNP allele
were themselves correlated signiﬁcantly with signatures of metabolic
diseases including plasma lipids, BMI, andmeasures of insulin resistance
[33]. Taking a more global approach, a recent eQTL metaanalysis in
approx. 8000 subjects identiﬁed several SNPs existing as cis-eQTLs at
one locus while also acting as trans-eQTLs at other loci, including one
at the 3′ UTR of the FADS1 gene which altered the expression of the
LDLR gene in trans [34]. Such studies highlight both the complexity
and the value gained from careful study of casual variants as determined
through gene expression measurements.
Because it is not always possible to identify eQTLs from a given spec-
trum of SNPs at a locus or because eQTLs may be identiﬁed at loci for
genes with unknown biological function, additional experimental ap-
proachesmay allow further identiﬁcation of causal genes. One approach
has been the in vivo overexpression or knockdown of candidate genes at
a locus in animal models. The initial GLGC GWAS reported such work for
3 candidate genes inﬂuencing HDL-C: GALNT2, PPP1R3B and TTC39B [16].
In accompanyingwork, hepatic SORT1 (but not PSRC1) overexpression in
hypercholesterolemicmice demonstrated substantial reduction in LDL-C
levels, directionally consistent with the eQTL data in human liver and
providing strong evidence that the causal gene at the LDL-associated
chromosome 1p13 locus was SORT1 (see below for more discussion)
[20]. An ongoing effort in our laboratory has utilized this approach of
somatic overexpression and knockdown in mice to systematically inter-
rogate gene(s) at many of the novel loci reported in the 2010 GLGC
GWAS for effects on plasma lipids in vivo. Others are utilizing comple-
mentary approaches in cellular models through overexpression andsiRNA knockdown [35,36] or genome editing using transcription
activator-like effector nuclease (TALEN) and clustered regularly inter-
spaced palindromic repeat DNAs (CRISPR)/Cas9 nuclease genome-
editing methodologies [6,37,38].
5. New biology inspired by common variant studies
Among themultiple novel lipid loci borne from recent GWAS, several
have revealednewbiological paradigms for the genetic andphysiological
regulation of lipoprotein metabolism. Additionally, synergistic common
and low-frequency (MAF between 0.01 and 0.05) variant-focused
approaches that have emerged in the post-GWAS era have allowed for
further studies of loci that were lipid candidate genes before the emer-
gence of GWAS. In an effort to illustrate examples of how follow-up stud-
ies may be performed for such loci, we have chosen to discuss 3 novel
loci from GWAS, SORT1, TRIB1, and GALNT2. Functional studies of
these genes beneﬁted from localization of their tissue sites of action
with regard to lipoprotein metabolism (in the case of these 3, the
liver), development of tools for somatic gene manipulation in liver, and
in the case of GALNT2, identiﬁcation of functional coding variation
through sequencing at the phenotypic extremes. We close by highlight-
ing a pre-GWAS lipid-modifying gene, LIPG, to demonstrate the utility of
additional tools such as exome-wide genotyping and targeted sequenc-
ing, to further reﬁne loci in the post-GWAS era. In doing so, however,
we do note that there are many other lipid genes that were identiﬁed
and studied functionally before GWAS that were then subsequently
validated as candidate loci through GWAS; many of these have been
reviewed recently [39]. We summarize those genes identiﬁed through
unbiased genomic approaches as lipid candidate genes that have subse-
quently undergone validation as candidate genes in vivo in Table 1.
5.1. SORT1 (sortilin)
SNPs at the chromosome1p13 locuswere among the ﬁrst associated
with both CAD and LDL-C levels in GWAS, dating back to the original
Wellcome Trust Case Control Consortium GWAS for CAD in 2007 [40].
Subsequent studies have validated the associations between this locus
and LDL-C and CAD in large European and non-European cohorts.
Homozygosity for theminor allele of the lead SNP at this locus (approx-
imately 25%minor allele frequency in Europeans)was associatedwith a
16 mg/dL decrease in plasma LDL-C and 40% reduction in risk of MI [8].
The locus contains several genes in close proximity to the lead SNPs,
including SORT1, CELSR2, and PSRC1; none of whichwere previously im-
plicated in LDL metabolism.
Initial work aimed at identifying both the casual variant and the
causal gene at this locus underlying the association with lipids and pro-
tection from disease [20]. The lead SNPs for association with plasma
lipids occur in a noncoding region between PSRC1 and CELSR2, but this
region is also close in proximity to SORT1. Adding further complexity,
expression of all three genes is elevated by the minor allele of the SNP
at the locus in eQTL analyses of human liver samples but not in subcuta-
neous or omental adipose samples. Through ﬁne mapping, generation of
bacterial artiﬁcial chromosome constructs expressing different alleles of
the SNP haplotype, luciferase reporter assays, and additional functional
studies,Musunuru et al. showed that theminor allele of the causal variant
within a cis-regulatory region, rs12740374, created a de novo C/EBP tran-
scription factor binding site that causedC/EBP-dependent upregulation of
expression of the nearby genes [20].
In the same study, as noted above, adeno-associated virus (AAV)
vectorswere used to effect liver-directed gene transfer anddemonstrated
that hepatic SORT1 overexpression, but not PSRC1 overexpression, mark-
edly reduced plasma LDL-C levels in hypercholesterolemic mice. This
ﬁnding was directionally consistent with the human genetics data
showing that the minor allele at rs12740374 substantially increased
SORT1 expression and reduced plasma LDL-C. By contrast, the lack of
effect on LDL-C by PSRC1 overexpression suggested that this gene
Table 1
Novel lipid genes identiﬁed through genome-wide approaches with in vivo functional validation.
Gene name Associated lipid trait(s) eQTL (tissue) Proposed mechanism Reference
Genes identiﬁed through GWAS
PPP1R3B HDL-C, LDL-C, TC Yes (liver) Unclear 16
TTC39B HDL-C, TC No Unclear 16
GALNT2 HDL-C, TG Yes (liver, plaque) Unclear, evidence for regulation of ANGPTL3 cleavage in vitro and ApoC-III glycosylation in human plasma 16, 56–61
SORT1 LDL-C, TC Yes (liver) Regulation of VLDL secretion, regulation of hepatic LDL uptake 16, 20, 42–47
TRIB1 HDL-C, LDL-C, TC, TG No Regulation of hepatic lipogenesis 16, 52–55
Genes harboring coding variants identiﬁed through exome array genotyping
PCSK7 HDL-C No Regulation of ANGPTL4 cleavage/activity 84
ANGPTL8 HDL-C No Activation of ANGPTL3 84
COL18A1 TG No Regulation of LPL localization 84
TM6SF2 TC No Unclear 85
Genes harboring coding variants identiﬁed through exome sequencing
LIPA LDL-C No Unclear 96
ANGPTL3 LDL-C, HDL-C, TG, TC No Inhibition of lipases 96
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association.
SORT1 encodes sortilin, a multi-ligand cell-surface receptor and
intracellular trafﬁcking chaperone with endolysosomal sorting motifs.
It was hypothesized that it may promote trafﬁcking and presecretory
degradation of VLDL in hepatocytes (a process previously described
but without a molecular mechanism [41]) as a mechanism to reduce
VLDL secretion and eventually circulating LDL-C levels. Indeed, overex-
pression of SORT1was shown to reduce VLDL TG and apolipoprotein B
(apoB) secretion in mice [20].
However, studies of SORT1 knock-out (KO) mouse models have
highlighted its complexity in VLDL and LDL metabolism. Soon after the
initial report by Musunuru et al., Kjolby, et al reported a SORT1 KO
mouse, whichwhen crossed to an LDLR-deﬁcient background exhibited
lower LDL-C and reduced VLDL secretion [42]. Themousemodel used in
these studies was a SORT1 deletion mutation resulting from disruption
of exon 14, resulting in some aberrant protein being expressed [43,
44]. However, another SORT1 KO model, demonstrating complete lack
of SORT1 expression [45], was subsequently also shown to have reduced
VLDL secretion [46]. Thus, both hepatic overexpression and complete
deﬁciency of SORT1 reduce VLDL secretion in mice. This paradoxical
ﬁnding remains to be fully explained.
Sortilin trafﬁcs to the plasma membrane and has several known ex-
tracellular ligands that it binds and chaperones to the lysosome [47].
LDL was shown to have high afﬁnity for sortilin by surface plasmon res-
onance and to be taken up and degraded at a higher rate by liver cells
overexpressing sortilin [46]. Moreover, hepatic overexpression of
sortilin resulted in faster catabolism of LDL in vivo in mice, and this
also occurred in LDLR deﬁcientmice, indicating that the effectwas inde-
pendent of the LDL receptor. In contrast, sortilin deﬁcient mice had
slower catabolism of LDL and this was also true in LDLR deﬁcient mice
[46]. These studies demonstrated that sortilin binds LDL directly and is
a physiologically relevant cell-surface LDL receptor in the liver, suggesting
a complex orchestration of LDL metabolism by this protein. Returning to
the human genetics, increased expression of sortilin in the liver might be
expected to both reduce VLDL production and increase LDL catabolism,
perhaps accounting for the very strong association of the minor allele
(causing elevated sortilin expression) with lower levels of LDL-C. While
much more work on the cell biology and physiology is needed, it is safe
to say that GWAS ﬁrst put sortilin on the map as a molecule relevant to
LDL metabolism in humans.
5.2. TRIB1 (tribbles-1)
TRIB1was also among the initial loci implicated in inﬂuencing plasma
lipids in the ﬁrst GWAS for plasma lipids [8,9]. Lead SNPs are located on
chromosome 8p24 approximately 40 kb away from the TRIB1 gene.
SNPs at this locus are among the handful of SNPs associated with allmajor plasma lipid traits (TG, HDL-C, LDL-C); the minor allele at the
lead SNP is associated with the atheroprotective lipid proﬁle of reduced
TG, reduced LDL-C and increased HDL-C [16]. Indeed, in addition to
being associatedwith a favorable lipid proﬁle, these SNPs have been asso-
ciated with signiﬁcantly reduced risk of CAD in both GWAS of large
European populations and in gene-centric array association studies [16,
17,48,49]. Additionally, these SNPs have been associated with related
metabolic phenotypes such as plasma adiponectin levels and serum
transaminases [50,51].
No known liver eQTLs exist for the SNPs at this locus. However, given
the high level of expression of TRIB1 in the liver, the association of TRIB1
SNPs with serum transaminases, and the prominent role of the liver in
lipoprotein metabolism, the liver has been the focus of much work on
relating TRIB1 to plasma lipid levels. Using a design similar to the initial
in vivo validation of SORT1, TRIB1was somatically overexpressed in the
liver in mice and produced a reduction in plasma TG and cholesterol
through impaired VLDL secretion [52]. In contrast, TRIB1 KO mice dem-
onstrated elevated plasma TG and cholesterol and increased VLDL
secretion. Differences in plasma lipids in the overexpression and KO
models were accompanied by reciprocal differences in hepatic expres-
sion of lipogenic genes, suggesting that TRIB1may regulate lipogenesis
in vivo. TRIB1 encodes a protein called tribbles-1 that is a cytosolic scaf-
folding proteinwith a poorly deﬁnedmolecular function in the liver [53,
54]. Work on how the hepatic tribbles-1 protein may mediate these
effects on lipogenesis is currently ongoing.
Additionally, TRIB1may inﬂuence lipid metabolism through extra-
hepatic roles. One recent study of mice with TRIB1 deﬁciency in the
spleen and hematopoietic cells including macrophages demonstrated
increased lipolysis in thesemice [55]. Consequently, thesemice exhibited
elevated serum free fatty acids, less adipose mass, elevated cholesterol,
TG, fasting glucose, and insulin resistance on a high-fat diet relative to
wild-type controls. The results of this study and the previous one focused
on hepatic TRIB1 function suggest that this genemay contribute to meta-
bolic phenotypes through actions in multiple tissues.5.3. GALNT2 (polypeptide N-acetylgalactosaminyltransferase 2)
SNPswithin intron 1 ofGALNT2 at chromosome1q42 have been con-
sistently associated with HDL-C and TG in multiple GWAS [8,9,15–17].
The lead SNP at this locus, rs4846914, has a minor allele frequency of
40% in Europeans and is associatedwith decreasedHDL-C and increased
TG. In addition to fasting lipids, this SNP has been associated with rare
Fredrickson hyperlipoproteinemias in a smaller case–control study of
386 cases and 242 controls [56]. In addition to lipid traits, SNPs at this
locus have also been related to several nonlipid traits in a recent
‘phenome’-wide association study, including serum calcium levels and
circulating white blood cell count, among other traits [57]. GALNT2
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had never been implicated previously in lipoprotein metabolism.
Given the presence of the lipid-associated SNPs within an intron of
GALNT2 and lack of any genes for several 100 kb either upstream or
downstream, GALNT2 has regularly been considered to be the causal
gene driving the lipid association signal at this locus [7]. Only one eQTL
study implicating lipid-associated SNPs at this locuswithGALNT2 expres-
sion has been reported. Folkersen et al. examined 166 SNPs associated
with lipid/cardiovascular traits and related the genotype at these SNPs
to expression level of most proximal genes in human liver, aorta, mam-
mary artery, and atherosclerotic plaque tissues [58]. The authors demon-
strated thatGALNT2 expressionwas signiﬁcantly increasedwith the allele
at the lead SNP rs4846914 associated with increased HDL-C in both liver
and atherosclerotic plaque.
This directionality conﬂicts with initial physiological studies of
GALNT2 expression or activity in animals and humans. Somatic AAV-
mediated overexpression ofmouseGALNT2 in the livers ofmice resulted
in decreased plasma HDL-C and increased TG, while AAV-mediated
short hairpin RNA (shRNA) knockdown had reciprocal effects [16]. Ad-
ditionally, sequencing of the gene in individuals with elevated HDL-C
identiﬁed humans heterozygous for a missense variant D314A in
GALNT2 that was reported to have reduced catalytic activity in vitro
[59]. Compared with non-carrier controls, these individuals had im-
proved postprandial TG clearance and reduced sialylation of ApoC-III,
suggesting that the missense variant confers loss-of-function. Indeed,
apoC-III was found independently to be a target of GALNT2 in liver
cells in vitro; a number of other plausible candidate proteins have also
been identiﬁed as GALNT2 targets [60,61].
Efforts, both through human genetics and model systems, are un-
derway to conﬁrm the true directionality of association of GALNT2
expression/activity and HDL-C/TG levels and the mechanisms by
which GALNT2 inﬂuences lipoprotein metabolism.
5.4. LIPG (endothelial lipase)
Common variants at the LIPG locus (chromosome 18q21) have been
signiﬁcantly associatedwith HDL-C in multiple GWAS [8,9,16,17,62,63].
Follow-up of the lead SNPs at this locus demonstrated signiﬁcant asso-
ciationswith related traits such asHDL subclasses, HDL particle number,
and ApoA-I level [64,65]. These SNPs were also associated with in-
creased plasmaELmass levels, suggesting that they directly or indirectly
increase expression of LIPG [65]. Unlike the previous three examples,
however, LIPG was a lipid-modifying candidate gene for several years
before it had an established relationship to plasma lipids based on
human genetics studies. Initially reported by two groups independently
in 1999 [66,67], LIPG and its protein product endothelial lipase, EL, were
studied in vivo through overexpression and KO mouse models. LIPG
overexpression caused markedly reduced HDL-C in vivo while deletion
of LIPG [68,69] or antibody-based inhibition of EL [70] raised HDL-C.
Subsequent biochemical studies established EL as a phospholipase that
exhibited preference of HDL as a substrate, suggesting that EL-mediated
HDL lipolysis may be a mechanism by which EL reduces HDL levels
in vivo.
Todetermine a role for LIPG in regulatingHDL-C inhumans, the coding
regions in LIPG were sequenced in more than 500 subjects of European
ancestrywith either extremely high or lowHDL-C and 7 uniquemissense
mutationswere identiﬁed, all of whichwere exclusive to individualswith
high HDL-C [71]. Testing these rare variants for effects on EL function
in vitro demonstrated that they were all deleterious to protein catalytic
function. This established a role for rare coding variation in LIPG as a
cause of raised HDL-C in humans as well.
In addition to the rare variants, a low-frequency missense variant
Asn396Ser (rs77960347) and a common missense variant Thr111Ile
(rs2000813) were genotyped and tested for their possible functional
effects on EL activity. The Asn396Ser variant was highly associated
with increased HDL-C and compared with wild-type EL exhibitedimpaired lipase activity in vitro and in vivo when expressed using
AAV in LIPG KO mice [71]. More recently, this coding variant was dem-
onstrated to be among the most signiﬁcantly associated with HDL-C
levels in a large ‘exome’-array association study of N200,000 low-
frequency and rare coding variants in N56,000 individuals of mixed
European and African American ancestry [72]. The robust association
of this variant with HDL-C independently of other plasma lipid traits
and low but not rare allele frequency allowed further interrogation of
how LIPG-mediated effects on HDL-C may inﬂuence downstream traits
such as risk of CAD. This variant was used as an instrument to test
the independent causality of LIPG-mediated HDL-C elevation and
CAD incidence in a Mendelian Randomization study by Voight et al.
in N20,000 MI cases and N95,000 controls [73]. Though Asn396Ser
carriers in this study had substantially higher HDL-C as expected, this
elevation was not associated with protection from CAD, suggesting
that alterations in HDL-C through EL inhibition alone may be unlikely
to result in protection from risk of disease.
In contrast to Asn396Ser, the common missense variant Thr111Ile
did not exhibit altered EL activity in vitro or in vivo [71]. However,
this variant exhibited positive association with HDL-C in the larger
GLGC study [16,65], which suggested that itmight be in LDwith variants
conferring a functional effect on either LIPG expression or function. In a
sequencing study of noncoding variation in LIPG in persons at extremes
of HDL-C, we identiﬁed several rare and common promoter polymor-
phisms and tested their functional effect using reporter assays. We
found one common promoter variant, rs344747347, in the 5′ untrans-
lated region (UTR) of LIPG that impaired reporter gene expression
in vitro and was associated with lower EL mass levels in plasma of 761
genotyped subjects. We found that this variant is in high LD with the
Thr111Ile variant (R2 = 0.8) and may underlie the association of this
nonfunctional coding variant with HDL-C [65]. This example illustrates
how even coding variants are not always causal for an association and
that a noncoding variant in LD with a coding variant can actually be
the causal variant.
6. Looking ahead—leveraging low-frequency variants, Mendelian
randomization, and sequencing
As the ﬁeld of lipid genetics moves beyond GWAS to focusing on
identiﬁcation of causal variants, causal loci, and biological mechanisms
underlying novel genes, additional tools and approaches have emerged
to aid these efforts. Customized SNP arrays focused on speciﬁc diseases/
traits have allowed dense genotyping of emerging candidate loci in large
populations. One such example is the Metabochip array, a 200,000 SNP
array that follows up on the most highly associated variants from
GWAS metananalyses of plasma lipids, type 2 diabetes, CAD and MI loci
[74]. This arrayhas been subsequently used to drawassociations between
lipid-associated loci and many other related traits through ﬁne-mapping
[15,74–78]. Other such arrays exist to interrogate SNPs focused on spe-
ciﬁc constellations of metabolic, anthropometric, and disease-focused
traits.
One focus has been the attempt to identify low-frequency variants of
strong effect sizes on plasma lipids that also associate with disease risk.
This effort has been fueled in part by the discovery of functional low-
frequency coding variants in PCSK9, a negative regulator of the LDL
receptor. More than a decade ago, linkage mapping identiﬁed gain-of-
function coding variants that caused hypercholesterolemia and were
positively associatedwith CAD risk, and subsequently, sequencing indi-
viduals with extremely low LDL-C identiﬁed loss-of-function coding
variants that were also associated with protection from disease
[79–81]. These studies were crucial in establishing PCSK9 as a causal
contributor to LDL-C levels and risk of CAD in humans and led to a
rapid effort to understand both the biology and the therapeutic poten-
tial of targeting this protein [82]. To increase the throughput of identify-
ing functional coding variants of low-frequency at a cost more
manageable than currently possible for exome sequencing, an exome-
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developed [83]. Peloso et al. recently used this array to genotype
N200,000 low-frequency and rare coding sequence variants in N56,000
individuals of European and African American ancestry [84]. This study
identiﬁed four new low-frequency variants in novel genes inﬂuencing
HDL-C and/or TG: ANGPTL8, PAFAH1B2, COL18A1, and PCSK7. Overex-
pression of one of these, PCSK7, in mice resulted in elevated TG and re-
duced HDL-C levels. Despite their robust lipid association, the coding
SNPs in these genes were not associated with changes in risk of CAD in
this study. Another recent study applied the exome array to genotype
N80,000 coding variants in N5600 individuals of European ancestry and
subsequently followed up on 10 loci with genome-wide associations
for a coding variant with a lipid trait in an additional cohort. This work
identiﬁed a novel candidate gene, TM6SF2, at a known locus on chromo-
some 19 containing NCAN/CILP2/PBX4. The coding variant, Glu167Lys,
was common (MAF 0.087) and associated with lower total cholesterol.
Adenoviral overexpression of this gene in mice raised total cholesterol
while adenoviral knockdown with shRNA reduced plasma cholesterol,
suggesting a physiological role for this newly identiﬁed gene in regulat-
ing plasma cholesterol levels. This variant was also associated with re-
duced risk of MI, thus providing another example of the utility of the
exomearray coding variant genotyping-focused approach for elucidating
variants of relevance to both intermediary lipid traits and disease risk
[85].
Currently, low-frequency variants inﬂuencing lipids, whether coding
or noncoding, have also allowedpreliminary interrogation of the causality
of these lipid biomarkerswith risk of disease. These causality studies have
been informally called Mendelian randomization studies and ascertain
the effects of randomized collections of variants assigned at meiosis and
independent assortment [86,87]. Using variants with robust associations
with an intermediary phenotype (e.g. plasma lipid type), one can interro-
gate the deviation of the predicted effect of a variant on a secondary trait
(e.g. disease risk) based on the impact the variant has on the intermediary
trait. These approaches allow study of the causality of variants without
traditional limitations of observational epidemiological studies such as
confounding and reverse causation (the onset of disease before alteration
in intermediary biomarker) [88]. These studies rely on lack of pleiotropic
effects of the variants of interest, which can rarely be measured compre-
hensively, thus adding a caveat to interpretation of results of these efforts.
Mendelian randomization using variants associated with HDL-C at the
LCAT, CETP, APOA1, ABCA1, LIPC, and, as discussed above, LIPG loci have
been used to test the causal relationship between HDL-C and CAD.
These investigations have largely failed to support a strong causal
relationship between HDL-C and risk of CAD [89–92]. Whether it will be
possible to perform analogous studies to investigate the causal relation-
ship of functional aspects of HDL, such as cholesterol efﬂux capacity, as
opposed to HDL-C levels, will depend on the identiﬁcation and ability to
test low-frequency genetic variants speciﬁcally inﬂuencing such traits.
Similarly to these HDL-C-focused efforts, a recentMendelian random-
ization study was carried out to test the association of TG-regulating loci
with risk of CAD [93]. Using amodiﬁed approach, the investigators tested
185 SNPs for association and effect sizes on all lipid traits in the N188,000
individuals of the most recent GLGC cohort. Then, focusing on SNPs with
large effect sizes on TG but not on LDL-C, they tested the relationship of
the effect size of a SNP on TG with that on CAD risk in N86,000 subjects
in the CARDIoGRAM study. This approach demonstrated highly signiﬁ-
cant causal relationships between SNPs at multiple TG loci with CAD.
Candidate gene and whole exome sequencing permit the identiﬁca-
tion of very rare and privatemutations thatmay be causal for lipid traits.
An example of the power of candidate gene sequencing is the work by
Johansen, Hegele and colleagues, who resequenced candidate genes
for hypertriglyceridemia (HTG) identiﬁed from GWAS in a case–control
design. They found a signiﬁcant burden of rare missense or nonsense
coding variants in these candidate genes in HTG cases relative to con-
trols [94]. Motazacker et al. recently reported a targeted sequencing
study of 195 lipid candidate genes and 78 non-lipid genes in a smallcohort of subjects at extremes of the HDL-C distribution. The authors
showed an increased frequency of rare nonsynonymous variants in
lipid genes, but not non-lipid genes, in individuals with extremely
high or extremely low HDL-C levels relative to the general population
and normal HDL-C participants [95]. Exome sequencing of individuals
at extremes of lipid traits or even whole populations will reveal addi-
tional insights, especially for genes conferring risk by recessive modes
of inheritance. Exome sequencing in a family with familial combined
hypolipidemia identiﬁed loss-of-function mutations in ANGPTL3 as a
cause of this inherited lipid disorder [96]. Another recent example by
the National Heart Blood and Lung Institute GO Exome Sequencing
Project involved sequencing in three family members with autosomal
recessive hypercholesterolemia lacking mutations in known candidate
genes. Exome sequencing of these family members revealed a novel
splice-site mutation in the LIPA gene that segregated with the hyper-
cholesterolemia diagnosis andwith accumulation of hepatic cholesterol,
the latter of which had been reported previously in patients with other
mutations in LIPA [97]. Using a case–control design, another recent
study sequenced the exomes of 2500 subjects with either extremely
high or extremely low LDL-C and followed up by additional sequencing
in another N1300 subjects and exome array genotyping in N55,000 sub-
jects. This work identiﬁed signiﬁcant associations of rare or low-
frequency variants in known LDL-C modifying genes PCSK9, LDLR, and
APOB, but also a novel gene, PNPLA5. The authors noted that the effect
sizes of the low-frequency variants on LDL-C were greater than those
found for LDL-C associated common SNPs from GWAS, suggesting that
low-frequency focused approaches may be useful for identifying more
functionally signiﬁcant SNPs for certain traits [98].
In a fascinating example, personswith earlyMI or older controls were
subjected to exome sequencing. The gene with the greatest imbalance
between cases and controls for deleterious mutations was the LDLR,
and the second gene was the known triglyceride-regulating gene
APOA5 [82]. Such gene-based analyses of whole exome data are limited
by power and much larger studies will be needed to make deﬁnitive
conclusions regarding an excess ‘burden’ of mutations causing a trait or
disease. However, this approach, and ultimately whole genome sequenc-
ing, are the most unbiased ways to deﬁne the genetic architecture of
complex traits and diseases.
7. Summary
Awealth of novel lipid loci have been identiﬁed through a variety of
approaches focused on common and low-frequency variation and col-
laborative metaanalyses in multiethnic populations. Despite progress
in identiﬁcation of loci, the task of determining causal variants remains
challenging. This work will undoubtedly be enhanced by improved un-
derstanding of regulatory DNA at a genome-wide level as well as new
methodologies for interrogating the relationships between noncoding
SNPs and regulatory regions. Equally challenging is the identiﬁcation
of causal genes at novel loci. Someprogress has beenmade for a handful
of genes and comprehensive testing of candidate genes using multiple
model systems is underway. Additional insights will be gleaned from
focusing on low-frequency and rare coding variation at candidate loci
in large populations.
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